

SHREE GANESH BIO-TECH (INDIA) LIMITED

CIN:L70101WB1982PLC121196

Reg. Office: 6TH FLOOR, PREMISES 602, MAHAVIR APARTMENT 2, ASHUTOSH MUKHERJEE ROAD KOLKATA-700020

Email: shreeganeshbiotechindiaLtd@gmail.com

Date: 04.02.2019

To,
Listing Department,
BSE Limited,
P J Tower, Dalal
Street
Mumbai-400001

To,
The Secretary,
The Calcutta Stock
Exchange Ltd,
7, Lyons Range,
Kolkata - 700001

To,
Head - Listing
Metropolitan Stock Exchange of
India Limited
Vibgyor Towers, 4th floor, Plot No
C 62, Opp. Trident Hotel Bandra
Kurla Complex, Bandra (E),
Mumbai - 400098

Scrip Code: 539470

Scrip Code: 29221

Scrip Code: SHREGANES

Dear Sir/Madam,

Sub: Submission of Audited Financial Result for quarter ended 31st December, 2018 pursuant to Regulation 33 of the SEBI (LODR) Regulations, 2015

Further to our letter dated 24th January, 2019, we would like to inform that the Board of Directors of the Company at its meeting held on today has approved Un-audited Financial Results for the first quarter ended 31st December, 2018

In terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are enclosing herewith the following:

1. Un-audited Standalone Financial Results for the third quarter ended 31st December, 2018.
2. Limited Review Report on the Standalone Financial Results


The Board meeting commenced at 15:00 Hrs and concluded at 16:00 Hrs We request you to take the same on records.

Thanking you.

Yours faithfully,

FOR, SHREE GANESH BIOTECH (INDIA) LTD

DIRECTOR, AUTHORIZED SIGNATORY



Shree Ganesh Biotech (India) Ltd

CIN:- L70101WB1982PLC121196

Regd. Office: 6th Floor, Premises - 602, Mahavir Apartment, 2, Ashutosh Mukherjee Road, Kolkata - 700020

Email:- shreeganeshbiotechindia@gmail.com


Statement of Unaudited Financial Results for the Quarter Ended December 31, 2018

SI no.	Particulars	Quarter Ended 31 Dec'2018	Quarter Ended 30 Sept'2018	Quarter Ended 31 Dec'2017	Nine Monts Ended 31 Dec'2018	Nine Monts Ended 31 Dec'2017	Year Ended 31 Mar 2018
	(Refer Notes Below)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
1	INCOME						
(a)	Revenue from Operations	164.43	131.23	104.59	394.53	667.58	785.76
(b)	Other Income	-	-	-	-	-	-
	Total Income	164.43	131.23	104.59	394.53	667.58	785.76
2	EXPENSES						
(a)	Cost of material consumed	-	-	-	-	-	336.53
(b)	Purchase of stock in trade	92.30	73.85	55.75	230.40	261.50	-
(c)	Changes in inventories of finished goods, work-in-progress, and stock-in-trade	-	-	-	-	-	-
(d)	Employee benefit expense	1.20	2.59	0.75	4.99	2.30	9.66
(e)	Finance Costs	-	-	-	-	-	-
(f)	Depreciation and Amortization Expense	-	-	-	-	-	-
(g)	Other expenses	13.56	16.97	31.44	51.48	69.28	89.53
	Total Expenses	107.06	93.41	87.94	286.87	333.08	435.72
3	Profit for the Period before Share of Profit / (Loss) of Associates And Joint Ventures	57.37	37.82	16.65	107.66	334.50	350.04
4	Share of Profit/ (Loss) of Associates & Joint Venture	-	-	-	-	-	-
5	Profit before tax	57.37	37.82	16.65	107.66	334.50	350.04
6	Tax Expense	-	-	-	-	-	-
7	Net Profit after taxes and Share of Profit/ (Loss) of Associates and Joint Ventures but before non-controlling interests	57.37	37.82	16.65	107.66	334.50	350.04
8	Non-controlling interests	-	-	-	-	-	-
9	Net Profit after taxes, non-controlling interests and share of profit / (loss) of Associates and Joint Ventures	57.37	37.82	16.65	107.66	334.50	350.04
10	Other comprehensive income						
A.	(i) Items that will not be reclassified to profit or loss	-	-	-	-	-	-
	(ii) Income tax relating to items that will not be reclassified profit or	-	-	-	-	-	-
B.	(i) Items that will be reclassified to Profit or Loss	-	-	-	-	-	-
11	Total comprehensive income (9+10)	57.37	37.82	16.65	107.66	334.50	350.04
14	Paid-up equity share capital (Face Value of Rs. 10/- each)	1,993.12	1,993.12	183.12	1,993.12	183.12	183.12
15	Other Equity						2,103.84
16.i	Earnings Per Share (before extraordinary items) (of Rs. 10/- each) (not annualised):						
	(a) Basic	0.29	0.19	0.91	0.54	18.27	19.12
	(b) Diluted	0.29	0.19	0.91	0.54	18.27	19.12
16.ii	Earnings Per Share (after extraordinary items) (of Rs. 10/- each) (not annualised):						
	(a) Basic	0.29	0.19	0.91	0.54	18.27	19.12
	(b) Diluted	0.29	0.19	0.91	0.54	18.27	19.12

Notes:

- 1 The above financial results have been reviewed by the Audit Committee and approved by the Board of Directors at its meeting held on February 04, 2019. The Statutory Auditors have carried out a limited review of the above financial result.
- 2 Company has only one segment and hence no separate segment result has been given.
- 3 The figure of previous period/year have been re-grouped / re-arranged and /or recast wherever found necessary.
- 4 This statement is as per Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015

Place : Ahmedabad
Date : 04th February, 2019





Limited Review Report

To
The Board of Directors of
Shree Ganesh Biotech (India) Ltd

We have reviewed the accompanying Statement of Standalone Unaudited Financial Results of Shree Ganesh Biotech (India) Ltd ("the Company"), for the Quarter ended December 31, 2018 ("the Statement"), being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as modified by Circular No. CIR/CFD/FAC/62/2016 dated July 5, 2016.

This Statement which is the responsibility of the Company's Management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued there under and other accounting principles generally accepted in India. Our responsibility is to issue a report on the Statement based on our review.


We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of Company personnel and an analytical procedure applied to financial data and thus provides less assurance than an audit. We have not performed an audit and, accordingly, we do not express an audit opinion.

Based on our review conducted as stated above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the aforesaid Indian Accounting Standards and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as modified by Circular No. CIR/CFD/FAC/62/2016 dated July 5, 2016, including the manner in which it is to be disclosed, or that it contains any material misstatement.

Place: VADODARA
Date: 04.02.2019



For Bipin & Co.
Chartered Accountants
FRNo.: 101509W


(CA Amit Shah)
Partner
M. No.: 126337